FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022 Journal of Pharmaceutical Innovation Springer Nature Link Triangle Compounding Pharmacy Inc, Cary, NC. 483 Issued 07 13 2017 On July 23 and July 23, 2026 from 8:00 am to 4:30 pm EST, the Food and Drug Administration, HHS, will be holding a public advisory meeting of the Pharmacy Compounding Advisory Committee in Silver FDA Peptide Update: Category 2 Removals Explained